AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aardvark Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.74−0.04 (-1.06%)
Close on Oct 19, 2026
- Market cap
- $81.70M
- P/E (TTM)
- –
- Dividend yield
- –
Aardvark Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Market Cap | $81.85M | $166.30M |
| Enterprise Value | $7.95M | $88.19M |
| PB Ratio | 1.09 | 2.03 |
| P/TBV Ratio | 1.09 | 2.29 |
Income (trailing twelve months)
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Revenue | $0 | $58.34M |
| Operating Income | -$73.96M | -$21.40M |
| Net Income | -$69.89M | -$22.46M |
| EBITDA | -$73.91M | -$16.91M |
| EPS (Diluted) | -$3.21 | -$0.83 |
Returns
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -66.0% | -53.2% |
| Return on Assets (ROA) | -61.1% | -40.9% |
| Return on Capital Employed (ROCE) | -98.5% | -38.1% |
Balance sheet
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $73.90M | $61.43M |
| Net Cash (Debt) | $73.90M | $15.35M |
| Net Cash Per Share | $3.38 | $0.66 |
| Equity (Book Value) | $74.80M | $49.09M |
| Book Value Per Share | $3.42 | $1.37 |
| Tangible Book Value | $74.80M | $23.52M |
| Working Capital | $74.27M | $76.81M |
Financial position
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 12.63 | 3.34 |
| Quick Ratio | 11.57 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$69.41M | -$12.35M |
Efficiency
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $0 | $404.87K |
| Profits Per Employee | -$1.75M | -$703.34K |
| Employee Count | 40 | 74 |
Dividends and yields
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -85.4% | -23.3% |
Shares
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 21,884,800 | 58,127,000 |
| Shares Change (YoY) | 103.1% | 10.9% |
| Shares Change (QoQ) | 0.31% | 0.54% |
| Float | 12,720,900 | 49,136,700 |
| Shares Held by Insiders | 41.9% | 11.6% |
| Shares Held by Institutions | 43.6% | 59.4% |
Scores
| Measure | Aardvark Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 2.86 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Aardvark Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.